Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Jan 31, 2023 2:21pm
180 Views
Post# 35257467

RE:RE:RE:RE:The Head, The Heart and The Gut

RE:RE:RE:RE:The Head, The Heart and The Gut

Rumpl3StiltSkin wrote:
tdon1229 wrote: OTOH, I'm not looking forward to having RDW back as CEO ... he's more of a science nerd from the laser side of the house ... he became more of a huckster the last time he held that office as he sought financing (the CFO's job), overstepped, and was censured and banished from leadership roles for five years ... unless he's grown significantly, I don't see him having the requisite capabilities for the challenges that lie ahead for this company and its ground-breaking technology ... lack of these capabilities is what dooms many promising companies to fail to recruit the needed personnel with skills and experience to carry the company forward ... we're about to enter what Harvard has dubbed the "Corridor of Crisis" wherein the entrepreneur who brought us this far is rendered functionally incapable of meeting the growing demands of the CEO position ... failure to recruit the necessary talent is what weighs down the company and keeps it from achieving its full potential ... 


TDon, lol. And I always thought you were RW? Lol. For some reason? Anyway, I think He will only have to navigate as far as the JV/Buyout. I think he has those skills, in spades...


 

A tremendous anmount of value has been created on a shoestring budget, & I have 100% confidence in the science & the clinical data moving forward.  The strong data/drug versatility/reduced risk & attractive pricing will certainly give us some leverage at the negotiation table.  However, it generally takes lots of cash to have an upper hand.  Having the ability to say "no" to Big Pharma can alone be worth north of $1 billion...all imo.  A good outcome for me would be a more friendly cash raise (post BTD/AA) & have at least one additional Ph1b under our belts for leverage sake.

It's been great to be see such a small company work its independence but at the end of the day, Pharma negotiations always start with the data but end with strength of cash...I hope management represents shareholders well.  Some may say they have earned a 2nd chance.  Good luck...

<< Previous
Bullboard Posts
Next >>